Qiagen N.V

Qiagen N.V. is a leading global provider of sample and assay technologies, dedicated to transforming biological samples into valuable insights for life sciences research, clinical diagnostics, and molecular medicine.

Founded in 1984, the company has established itself as a pioneer in the field of molecular biology, offering a wide range of products and services that enable researchers and healthcare professionals to unlock the potential of genetic information.

With a strong commitment to innovation, Qiagen invests heavily in research and development, ensuring that its offerings remain at the forefront of scientific advancements.

The company’s core activities include the development of kits and reagents for DNA, RNA, and protein extraction, as well as PCR and next-generation sequencing technologies.

Qiagen also provides bioinformatics solutions that facilitate data analysis and interpretation, empowering users to make informed decisions based on their findings.

Headquartered in Venlo, Netherlands, Qiagen operates in over 25 countries and serves customers in more than 150 countries worldwide.

The company’s vision is to enable customers to achieve breakthroughs in life sciences and healthcare by providing high-quality, reliable, and easy-to-use products.

Qiagen is committed to sustainability and corporate responsibility, actively working to reduce its environmental impact and contribute positively to the communities it serves.

Through strategic partnerships and collaborations, Qiagen aims to expand its reach and enhance its product offerings, ensuring that it remains a trusted partner in the scientific community.

As a publicly traded company on the New York Stock Exchange (NYSE: QGEN), Qiagen continues to demonstrate strong financial performance and growth potential.

In summary, Qiagen N.V. stands out as a key player in the biotechnology industry, dedicated to advancing science and improving patient outcomes through innovative solutions.